Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations - Summary - MDSpire

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

  • By

  • Raffaella Greco

  • Tobias Alexander

  • Joachim Burman

  • Nicoletta Del Papa

  • Jeska de Vries-Bouwstra

  • Dominique Farge

  • Jörg Henes

  • Majid Kazmi

  • Kirill Kirgizov

  • Paolo A. Muraro

  • Elena Ricart

  • Montserrat Rovira

  • Riccardo Saccardi

  • Basil Sharrack

  • Emilian Snarski

  • Barbara Withers

  • Helen Jessop

  • Claudia Boglione

  • Ellen Kramer

  • Manuela Badoglio

  • Myriam Labopin

  • Kim Orchard

  • Selim Corbacioglu

  • Per Ljungman

  • Malgorzata Mikulska

  • Rafael De la Camara

  • John A. Snowden

  • May 24, 2021

  • 0 min

Share

Objective:

To provide guidelines and recommendations for hematopoietic stem cell transplantation (HSCT) in patients with autoimmune diseases (ADs) during the COVID-19 pandemic, emphasizing the need to adapt to ongoing challenges.

Key Findings:
  • HSCT activity for ADs decreased by 52% during the pandemic compared to 2019, highlighting the need for careful patient management.
  • Multiple sclerosis (MS) and systemic sclerosis (SSc) accounted for 80% of HSCTs in ADs in 2020, indicating a focus on these conditions.
  • Guidelines emphasize careful discussion of HSCT cases in multidisciplinary teams (MDTs) and adherence to established protocols to ensure patient safety.
Interpretation:

The guidelines aim to balance the risks and benefits of HSCT in the context of ongoing COVID-19 challenges, ensuring patient safety and treatment efficacy while addressing specific risks associated with immunocompromised patients.

Limitations:
  • The guidelines are subject to change as new evidence emerges and the COVID-19 situation evolves, with variability in COVID-19 impact across different regions potentially affecting the applicability of guidelines.
Conclusion:

HSCT programs must adapt to the changing COVID-19 landscape, prioritizing patient safety while ensuring access to necessary treatments for ADs, with ongoing evaluation of guidelines as the situation evolves.

Original Source(s)

Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

  • by Raffaella Greco, Tobias Alexander, Joachim Burman, Nicoletta Del Papa, Jeska de Vries-Bouwstra, Dominique Farge, Jörg Henes, Majid Kazmi, Kirill Kirgizov, Paolo A. Muraro, Elena Ricart, Montserrat Rovira, Riccardo Saccardi, Basil Sharrack, Emilian Snarski, Barbara Withers, Helen Jessop, Claudia Boglione, Ellen Kramer, Manuela Badoglio, Myriam Labopin, Kim Orchard, Selim Corbacioglu, Per Ljungman, Malgorzata Mikulska, Rafael De la Camara, John A. Snowden

  • May 24, 2021

Related Content

Deliberations on Government Spending Priorities: Listen to the People

CAR-T cell therapy embarks on autoimmune disease

Severe Parvovirus B19–Associated Myocarditis in Children in the Post–COVID-19 Era: A Multicenter Observational Cohort Study